Anavex Life Sciences Corp (AVXL)

[polarbear77]

Thanks for the reply, Falconer, and as you're already aware, in 6 weeks at the GII sept 2017 conference they plan to present to the public (abstract link): http://www.giiconference.com/gtc515394/cns-partnering-deal-making.shtml

"In addition, data from an ongoing Phase 2a clinical trial in Alzheimer’s Disease demonstrates dose dependent cognitive improvements. The compound also exhibits anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat a broad range of CNS disorders."

My take: they aren't saying "improvements over SOC" instead to me it reads that the patients improve over their baseline from start of study. (which is what slide 26 of their Jefferies presentation in June 2017 reflects through week 53, and if my memory serves, there was a twitter/ihub poster named Peter Karol that was graphing similar improvement results based on his own research of a2-73 last Fall).

Mustn't they have a high level of confidence at this stage in the data to make this type of statement to the public and investment community?(assuming my read is correct)